Workshop details | Elsevier Researcher Academy
Sign up to this workshop 29 October 2020 08:30 (local time) Description Finding the right journal to publish your research and structuring your research…
Related Articles
The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9th) Edition of the TNM Classification of Lung Cancer
The goal of surgical resection is to completely remove a cancer; it is useful to have a system to describe how well this was accomplished.…
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion,…
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion,…
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC
“Don’t be afraid to give up the good to go for the great.”John D. Rockefeller
Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG)
The standard therapy for stage I NSCLC is surgery, but some operable patients refuse this option and instead undergo radiotherapy. Carbon-ion radiotherapy (CIRT) is a…
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
Extensive-stage small cell lung cancer (ES-SCLC) prognosis remains poor. The phase 3 RATIONALE-312 study aimed to evaluate efficacy and safety of tislelizumab plus chemotherapy as…
Lung Cancer in Switzerland
Currently, 8.7 million people live in Switzerland—a number that has more than doubled in the past 100 years. In the same time, the population has…
Unlocking Grant Success with Funding Institutional
Are you a researcher seeking efficient ways to secure funding? Join us to explore the power of Funding Institutional by Elsevier. With details on 40,000+ active…
Unlocking Grant Success with Funding Institutional
Are you a researcher seeking efficient ways to secure funding? Join us to explore the power of Funding Institutional by Elsevier. With details on 40,000+ active…